Teva Pharmaceutical Industries Ltd. said Thursday its third-quarter profit rose compared with the same period last year in large part because it stopped trying to sell generic medicine in markets where the profit was too small, cut expenses, and converted patients to a new version of its multiple sclerosis medication.